Clinical Trials Logo

Large Vessel Occlusion clinical trials

View clinical trials related to Large Vessel Occlusion.

Filter by:

NCT ID: NCT05659160 Recruiting - Clinical trials for Stroke, Acute Ischemic

Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2

TRACK-LVO-2
Start date: November 1, 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO), who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).

NCT ID: NCT05592054 Suspended - Clinical trials for Acute Ischemic Stroke

Proximal TEmporary oCclusion Using Balloon Guide Catheter for Mechanical Thrombectomy

PROTECT-MT
Start date: November 20, 2022
Phase: N/A
Study type: Interventional

A multi-center, prospective, randomized, open-label, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS.

NCT ID: NCT05496361 Completed - Clinical trials for Acute Ischemic Stroke

A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke

Start date: January 24, 2021
Phase: N/A
Study type: Interventional

This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel occlusion in the cerebral circulation.

NCT ID: NCT05437055 Recruiting - Clinical trials for Acute Ischemic Stroke

THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderboltâ„¢ Aspiration Tubing

Start date: August 11, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.

NCT ID: NCT05403593 Active, not recruiting - Clinical trials for Large Vessel Occlusion

Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS

RESCUE-ICAS
Start date: December 15, 2021
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to develop an international multicenter registry of patient data and outcomes for patients undergoing mechanical thrombectomy for emergent large vessel occlusion with residual underlying stenosis following successful revascularization.

NCT ID: NCT05342038 Withdrawn - Clinical trials for Acute Ischemic Stroke

Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke

T-02
Start date: April 22, 2022
Phase: N/A
Study type: Interventional

To examine the revascularization efficacy and safety of T-02 and its associated performance characteristics in treatment of appropriately selected subjects experiencing an acute ischemic stroke when the treatment is initiated within 24 hours after last seen well under the current guideline, and to generate hypotheses to be confirmed in subsequent confirmatory clinical investigations

NCT ID: NCT04726839 Recruiting - Stroke, Ischemic Clinical Trials

Biomarkers algOrithm for strOke diagnoSis and Treatment Resistance Prediction

BOOST
Start date: March 12, 2021
Phase:
Study type: Observational

Triage of acute ischemic stroke (AIS) patients is critical, to decrease time to treatment, and improve functional outcome. The therapeutic standard of care for AIS consecutive to large vessel occlusion (LVO) is the association of intravenous (IV) alteplase administration and mechanical thrombectomy (MT). However, there are limited places where MT can be performed. Therefore, there is a need for innovative tools to identify, in the ambulance, patients with LVO that require MT. Sending the patients at the right, avoiding futile stops (i.e. in places where MT is not available), is definitively a strategy that saves time. There is currently no biomarker nor Point Of Care (POC) Lab Testing to solve this issue and clinical scoring methods such as the NIHSS have a low accuracy rate to detect LVO. The relevance of blood biomarkers for LVO diagnosis and therapeutic decisions needs to be confirmed for effective triage in the setting of AIS with LVO, which represent 30% of all AIS. The main objective of our study is to determine diagnostic performances of a panel of selected blood biomarkers to identify patients with AIS consecutive to LVO among those with stroke suspicion, within 24 hours of stroke symptom's onset before brain imaging. This could facilitate the triage of patients with LVO refractory to thrombolysis treatment, who may benefit most from MT.

NCT ID: NCT04046757 Recruiting - Stroke Clinical Trials

Regional Strategy for Transfer for Mechanical Thrombectomy

START
Start date: October 1, 2019
Phase:
Study type: Observational

A mono-centre observational study with the aim of compare clinical outcome at 3 month on patients admitted with recent cerebral infarct and intracranial large vessel occlusion in the anterior circulation who are eligible for mechanical thrombectomy in three different position : Patients admitted first in the Comprehensive Stroke Center of Montpellier, those transferred after Proximity Stroke Unit or prehospital bypass for patients with high suspicion of large vessel occlusion.to the Comprehensive Stroke Center of Montpellier

NCT ID: NCT03753061 Recruiting - Clinical trials for Acute Ischemic Stroke

Intracranial Thrombosis Aspiration Catheter for Recanalization in Acute Ischemic Stroke Therapy (RECOVER)

Start date: November 22, 2018
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, open-label, end-point blinded, randomized, parallel positive control, non-inferiority clinical trial, with a purpose to evaluate the safety and efficacy of Hemo Jirui intracranial thrombus aspiration catheter system for endovascular treatment of acute ischemic stroke by comparison with stent retriever (Solitaire FR). The trial is anticipated to last from November 2018 to May 2019, with 204 subjects recruited from 15-20 clinical trial centers in China.

NCT ID: NCT03469206 Completed - Ischemic Stroke Clinical Trials

Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals

DIRECT-MT
Start date: February 21, 2018
Phase: N/A
Study type: Interventional

Background: Intravenous thrombolysis (IVT) combined with mechanical thrombectomy (MT) has been proven safe and effective in patients with acute ischemic stroke (AIS) of anterior circulation large vessel occlusion (LVO). Despite recanalization, a considerable proportion of patients do not recover. The incidence of symptomatic intracerebral hemorrhage (sICH) was similar between combined IVT plus MT and IVT, suggesting that this complication could not be attributed to the MT, but rather to pre-treatment with IVT. Meanwhile, the incidence of intracranial atherosclerosis stenosis (ICAS) is higher in Asians. It is not clear whether patients with ICAS benefit from pretreatment with alteplase or not and how ICAS modifies treatment effect. Objective: To assess whether direct MT is non-inferior compared to combined IVT plus MT in patients with AIS due to an anterior circulation LVO, and to assess treatment effect modification by presence of ICAD. Study design: This is a parallel group, RCT of direct MT compared to combined IVT plus MT, using a non-inferiority design. The trial has observer blinded assessment of the primary outcome and of neuro-imaging at baseline and follow up. The trial will be executed in collaboration with MRCLEAN NO-IV investigators. Study population: Patients with AIS of anterior circulation VLO confirmed by CTA. Initiation of IVT must be feasible within 4.5 hours from symptom onset. Age must be 18 or over and NIHSS 2 or more. Main outcomes: The full distribution of the mRS at 3 months. Secondary outcomes: 1. death within 90 +/- 14 days; 2. pre-interventional reperfusion assessed on first intracranial DSA; 3. eTICI19 score on final angiography of MT; 4. score on the NIHSS at 24 +/- 6 hours and 5-7 days, or at discharge; 5. recanalization rate at 24-72h by CTA; 6. Final lesion volume at 5-7 days on NCCT20; 7. score on the EuroQoL 5-dimensions 5-level (EQ5D-5L)21 and Barthel index22 at 90 +/- 14 days; 8. dichotomous clinical outcome on the mRS at 90 +/- 14 days.